European Commission approves Roche’s Gavreto to treat adults with RET fusion-positive advanced…
Gavreto is the first and only precision medicine approved in the EU for the first-line treatment of people with RET…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Gavreto
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations
Roche’s Genentech gets US FDA approval for Gavreto (pralsetinib)
The drug is used to treat metastatic RET fusion-positive non-small cell lung cancer